Improved Strategies for Relapsed NSCLC: New Regimens, New Combinations, and Targeted Therapies

Summary: In many clinical trials advanced non-small cell lung cancer has a mean survival of 8 to 11 months. There is a significant need for improved management strategies including new regimens, new combinations of regimens and the use of targeted therapies.